| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Pfizer Inc. | Tanezumab | Cancer pain | Phase 3 | Subcutaneous | Oncology | |
| Pfizer Inc. | Tanezumab | Chronic low back pain | Phase 3 | Subcutaneous | Orthopedic | |
| Pfizer Inc. | Tanezumab | Cancer pain | Phase 3 | Subcutaneous | Oncology | |
| Pfizer Inc. | Tanezumab | Chronic low back pain | Phase 3 | Subcutaneous | Orthopedic | |
| Pfizer Inc. | BAVENCIO (avelumab) - (JAVELIN Lung 100) | Metastatic non-small cell lung cancer (NSCLC) | Phase 3 | Intravenous | Oncology | |
| Pfizer Inc. | Palbociclib (PD-0332991) + Letrozole - (PALOMA-2) | ER+/HER2- advanced breast cancer | Phase 3 | Oral | Oncology | |
| Pfizer Inc. | PREVNAR 20 + COVID-19 Vaccine - (B74710126) | Pneumococcal + Covid-19 vaccine dual administration in 65< | Phase 3 | Intramuscular | COVID-19 | |
| Pfizer Inc. | PREVNAR 20 + seasonal influenza vaccine (SIIV, Fluad Quadrivalent) | Pneumonia and influenza for >65 yrs | Phase 3 | Data Released | Intramuscular | Respiratory |